

PARTICULARS TO APPEAR ON THE OUTER PACKAGE {10 vials of 1 dose}

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

ProteqFlu suspension for injection

2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES

One dose of 1 ml contains:

Influenza A/eq/Ohio/03 [H₃N₈] (vCP2242) ≥ 5.3 log₁₀
FAID₅₀

Influenza A/eq/Richmond/1/07 [H₃N₈] (vCP3011) ≥ 5.3 log₁₀
FAID₅₀

3. PACKAGE SIZE

10 x 1 ml (10 doses).

4. TARGET SPECIES

Horses

5. INDICATION(S)

6. ROUTES OF ADMINISTRATION

Intramuscular use.

7. WITHDRAWAL PERIODS

Withdrawal period: Zero days.

8. EXPIRY DATE

Exp. {dd/mm/yyyy}

Once opened use immediately.

9. SPECIAL STORAGE PRECAUTIONS

Keep the vial in the outer container

Store and transport refrigerated.

Do not freeze.

Protect from light.

10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”

Read the package leaflet before use.

11. THE WORDS “FOR ANIMAL TREATMENT ONLY”

For animal treatment only.

12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the sight and reach of children.

13. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Boehringer Ingelheim Vetmedica GmbH
55216 Ingelheim/Rhein
Germany

14. MARKETING AUTHORISATION NUMBER

Vm 04491/5047

15. BATCH NUMBER

Lot {number}

16. SPECIAL WARNING(S), IF NECESSARY

17. SPECIFIC PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY

Disposal: Read package leaflet

18. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE IF APPLICABLE

POM-V ('To be supplied only on veterinary prescription')
--

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
{Vial}

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

ProteqFlu 

2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCE(S)

1 dose

3. BATCH NUMBER

Lot {number}

4. EXPIRY DATE

Exp. {dd/mm/yyyy}
Once opened use immediately.

5. CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES

6. ROUTE(S) OF ADMINISTRATION

7. WITHDRAWAL PERIOD

8. THE WORDS “FOR ANIMAL TREATMENT ONLY”

For animal treatment only

PACKAGE LEAFLET

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

ProteqFlu suspension for injection

2. COMPOSITION

One dose of 1 ml contains:

Active substances:

Influenza A/eq/Ohio/03 [H₃N₈] recombinant canarypox virus (vCP2242) ≥ 5.3 log₁₀ FAID₅₀*

Influenza A/eq/Richmond/1/07 [H₃N₈] recombinant canarypox virus (vCP3011).. ≥ 5.3 log₁₀ FAID₅₀*

* vCP content checked by global FAID₅₀ (fluorescent assay infectious dose 50%) and qPCR ratio between vCP.

Adjuvant:

Carbomer

.....4 mg

Homogeneous opalescent suspension

3. TARGET SPECIES

Horses

4. INDICATIONS FOR USE

Active immunisation of horses of 4 months of age or older against equine influenza to reduce clinical signs and virus excretion after infection.

Onset of immunity: 2 weeks after primary vaccination course.

Duration of immunity induced by the vaccination scheme: 5 months after primary vaccination course and 1 year after the third vaccination.

5. CONTRAINDICATIONS

None.

6. SPECIAL WARNINGS

Vaccinate healthy animals only.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

Pregnancy and lactation:

Can be used during pregnancy and lactation.

Interaction with other medicinal products and other forms of interaction:

No interaction has been observed when the vaccine was administered simultaneously, but at a separate site, with Boehringer Ingelheim's inactivated vaccine against rabies.

Overdose:

Following the administration of overdoses of vaccine, no adverse events other than those described under section "Adverse events" have been observed.

Major incompatibilities:

Do not mix with any other veterinary medicinal product.

7. ADVERSE EVENTS

Horses:

Rare
(1 to 10 animals / 10,000 animals treated):
Injection site swelling ¹ , increased skin temperature, muscle stiffness, injection site pain Elevated temperature ²
Very rare
(<1 animal / 10,000 animals treated, including isolated reports):
Injection site abscess
Apathy, decreased appetite ³
Hypersensitivity reaction ⁴

¹ transient, usually regresses within 4 days; in rare occasions, swelling can reach a diameter up to 15–20 cm, with duration up to 2–3 weeks that may require symptomatic treatment.

² max. 1.5 °C, for 1 day, exceptionally 2 days.

³ the day after vaccination.

⁴ which may require appropriate symptomatic treatment.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the local

representative of the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system. {<https://www.gov.uk/report-veterinary-medicine-problem>}.

8. DOSAGE FOR EACH SPECIES, ROUTES AND METHOD OF ADMINISTRATION

1st scheme – vaccination against equine influenza:

Administer one dose (1 ml of ProteqFlu), by intramuscular injection, preferably in the neck region, according to the following schedule:

- Primary vaccination course: first injection from 5-6 months of age, second injection 4-6 weeks later.
- Revaccination: 5 months after primary vaccination course followed by annual booster injections.

In case of increased infection risk or insufficient colostrum intake, an additional initial injection of ProteqFlu can be given at the age of 4 months followed by the full vaccination programme (primary vaccination course at 5-6 months of age and 4-6 weeks later followed by revaccination).

2nd scheme - vaccination against equine influenza and tetanus:

Administer one dose (1 ml), by intramuscular injection, preferably in the neck region, according to the following schedule:

- Primary vaccination course with ProteqFlu-Te: first injection from 5-6 months of age, second injection 4-6 weeks later.
- Revaccination:
 - 5 months after primary vaccination course with ProteqFlu-Te.
 - Followed by:
 - o against tetanus: injection of 1 dose at an interval of maximum 2 years with ProteqFlu-Te.
 - o against equine influenza: injection of 1 dose every year, alternatively with ProteqFlu or ProteqFlu-Te, respecting an interval of maximum 2 years for the tetanus component.

In case of increased infection risk or insufficient colostrum intake, an additional initial injection of ProteqFlu-Te can be given at the age of 4 months followed by the full vaccination programme (primary vaccination course at 5-6 months of age and 4-6 weeks later followed by revaccination).

9. ADVICE ON CORRECT ADMINISTRATION

For the administration of the vaccine, use sterile and antiseptic-free and/or disinfectant-free material.

Shake the vaccine gently before use.

Intramuscular use (preferably in the neck region).

10. WITHDRAWAL PERIODS

Zero days.

11. SPECIAL STORAGE PRECAUTIONS

Keep out of the sight and reach of children.

Store and transport refrigerated (2 °C – 8 °C).

Do not freeze.

Protect from light.

Do not use this veterinary medical product after the expiry date which is stated on the carton and vial label after Exp.

Shelf life after first opening the immediate packaging: use immediately.

12. SPECIAL PRECAUTIONS FOR DISPOSAL

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.

13. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS

Veterinary medicinal product subject to prescription.

14. MARKETING AUTHORISATION NUMBERS AND PACK SIZES

Vm 04491/5047

Box of 10 vials of 1 dose.

15. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST REVISED

Find more product information by searching for the Product Information Database 'PID' on www.gov.uk

December 2022

16. CONTACT DETAILS

Marketing authorisation holder:

Boehringer Ingelheim Vetmedica GmbH

55216 Ingelheim/Rhein

Germany

Manufacturer responsible for batch release:

Boehringer Ingelheim Animal Health France SCS

Laboratoire Porte des Alpes

Rue de l'Aviation

69800 Saint-Priest

France

Local representatives and contact details to report suspected adverse reactions:

België/Belgique/Belgien

Boehringer Ingelheim Animal
Health Belgium SA
Tél/Tel: + 32 2 773 34 56

Република България

Boehringer Ingelheim RCV GmbH & Co KG
Tel: +359 2 958 79 98

Česká republika

Boehringer Ingelheim spol. s r.o.
Tel: +420 234 655 111

Danmark

Boehringer Ingelheim Animal Health Nordics
A/S
Tlf: + 45 3915 8888

Deutschland

Boehringer Ingelheim Vetmedica GmbH
Tel: 0800 290 0 270

Eesti

Boehringer Ingelheim RCV GmbH & Co KG
Eesti filiaal
Tel: +372 612 8000

Ελλάδα

Boehringer Ingelheim Vetmedica GmbH.
Τηλ: +30 2108906300

España

Boehringer Ingelheim Animal Health España,
S.A.U.
Tel: +34 93 404 51 00

France

Boehringer Ingelheim Animal Health France,
SCS
Tél: +33 4 72 72 30 00

Hrvatska

Boehringer Ingelheim RCV GmbH & Co KG
Tel: +385 1 2444 600

Ireland

Boehringer Ingelheim Animal Health UK Limited

Tel: +353 1 291 3985

Ísland

Vistor hf.
Sími: + 354 535 7000

Lietuva

Boehringer Ingelheim RCV GmbH & Co KG
Lietuvos filialas
Tel: +370 5 2595942

Luxembourg/Luxemburg

Boehringer Ingelheim Animal Health Belgium SA
Tél/Tel: + 32 2 773 34 56

Magyarország

Boehringer Ingelheim RCV GmbH & CoKG
Magyarországi Fióktelep
Tel: +36 1 299 8900

Malta

Boehringer Ingelheim Animal Health UK Limited
Tel: +44 1344 746957

Nederland

Boehringer Ingelheim Animal Health Netherlands b
Tel: +31 20 799 6950

Norge

Boehringer Ingelheim Animal Health Nordics A/S
Tlf: +47 66 85 05 70

Österreich

Boehringer Ingelheim RCV GmbH & Co KG
Tel: +43 1 80105-6880

Polska

Boehringer Ingelheim Sp. z o.o.
Tel.: + 48 22 699 0 699

Portugal

Boehringer Ingelheim Animal Health Portugal,
Unipessoal,
Lda.: +351 21 313 5300

România

Boehringer Ingelheim RCV GmbH & Co KG
Viena - Sucursala București
Tel: +40 21 302 28 00

Slovenija

Boehringer Ingelheim RCV GmbH & Co KG
Podružnica Ljubljana
Tel: +386 1 586 40 00

Slovenská republika

Boehringer Ingelheim RCV GmbH & Co KG, o.z.
Tel: +421 2 5810 1211

Italia

Boehringer Ingelheim Animal Health
Italia S.p.A.
Tel: +39 02 53551

Κύπρος

Boehringer Ingelheim Vetmedica GmbH
Τηλ: +30 2108906300

Latvija

Boehringer Ingelheim RCV GmbH & Co KG
Latvijas filiāle
Tel: +371 67 240 011

Suomi/Finland

Vetcare Oy
Puh/Tel: + 358 201443360

Sverige

Boehringer Ingelheim Animal Health Nordics A/S
Tlf: + 46 (0)40-23 34 00

United Kingdom (Northern Ireland)

Boehringer Ingelheim Animal Health UK Limited
Tel: + 44 1344 746957


United Kingdom (Great Britain)

Boehringer Ingelheim Animal Health UK Limited
Tel: + 44 1344 746957

17. OTHER INFORMATION

The vaccine stimulates active immunity against equine influenza.

The vaccine strains vCP2242 and vCP3011 are recombinant canarypox viruses expressing the haemagglutinin HA gene from the equine influenza virus strains A/eq/Ohio/03 (American strain, Florida sublineage clade 1) and A/eq/Richmond/1/07 (American strain, Florida sublineage clade 2), respectively. After inoculation, the viruses do not multiply in the horse but express the protective proteins. As a consequence, these components induce immunity against equine influenza virus (H₃N₈).



Approved: 26 April 2023